COMIRNATY OMICRON XBB.1.5 30 micrograms/dose, injectable dispersion. mRNA vaccine (nucleoside-modified) against COVID-19 60 doses
Active ingredients: RAXTOZINAMÉRAN
Commercialized according to BDPMDispensing in France: Prescription only
Injectable dispersion60 dosesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- COMIRNATY OMICRON XBB.1.5 30 microgrammes/dose, dispersion injectable. Vaccin à ARNm (à nucléoside modifié) contre la COVID-19
- Pharmaceutical form
- dispersion injectable
- Route of administration
- intramusculaire
- Presentation description
- 10 flacons multidoses en verre de 6 doses
- Marketing authorisation holder
- BIONTECH MANUFACTURING (ALLEMAGNE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 4 Nov 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64548397CIP73027903CIP133400930279038Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RAXTOZINAMÉRANdispersion | 30 microgrammes · une dose de 0,3 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.